RxDoctor Payments DataLook up a doctor →

Mariam Hameed, MD

Pain Medicine · Columbia, MDNPI 1639333644

Payments from drug & device makers

$12,219in general payments, 2019–2025

Across 393 payments — averaging $31.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$5K
  • Boston Scientific$2K
  • Abbott$882
  • Nevro Corp.$697
  • Scilex Pharmaceuticals Inc.$584
  • Vertos Medical, Inc.$523
  • plus $3K from 36 others

What the payments were for

  • Travel & lodging$9608%
  • Food & beverage$11,24192%
  • Entertainment$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,219 in reported general payments places this provider in the 75th percentile of 144 pain medicine providers in Maryland.

See all pain medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$624,440
Medicare patients
632
Services billed
17,936

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nucynta ErTapentadol Hcl20$20,177
Lidocaine45$9,026
NucyntaTapentadol Hcl13$8,597
SymproicNaldemedine Tosylate15$6,671
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen227$5,745
Tizanidine Hcl340$4,515
Buprenorphine25$4,380
Diclofenac Sodium31$4,364
Gabapentin347$4,262
Oxycodone Hcl176$2,555
Pregabalin151$2,308
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen107$2,192
Cyclobenzaprine Hcl118$1,609
Nortriptyline Hcl68$1,253
Baclofen50$1,214

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Nucynta Er, Nucynta$386$28,77533 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 144 pain medicine providers in Maryland.

Other pain medicine in Columbia

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →